StockUS listing USDTILNASDAQHealthcareValue Trap

Precision BioSciences Inc(DTIL) Stock Analysis | Healthcare

USD --+0.00%
Reward48Moderate
Risk58Medium-High
75%Data
Thin -86% profit margin · Revenue growing 37272% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 282.46M
Reward Ratingⓘ48 Moderate reward assessment · 75% data coverage
Bottom 25% of stocksView factors
Risk Ratingⓘ58 Medium-High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on DTIL to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Precision BioSciences Inc?

, a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States.

AI Brief Pro

The brief on Precision BioSciences Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Precision BioSciences Inc?

, a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 282.46M, and a P/E ratio of 29.6x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (48)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap282.46M
Beta1.353
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
12,821 shares
$28k
34,744 shares
$30k
3-6months
0
0
6-9months
0
0
9-12months
8107,624 shares
$431k
37,081 shares
$34k